Radiopharmaceutical manufacturer IBA Molecular North America will become Zevacor Pharma, effective January 1.
The rebranding decision reflects a refined vision for the firm's future as a provider of molecular imaging and therapeutic products, as well as its close relationship with Zevacor Molecular, according to the company.
Both IBA Molecular North America and Zevacor Molecular are owned by nonprofit healthcare system Illinois Health and Science (IHS). IHS acquired the former North American subsidiary of Ion Beam Applications in July.
